Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Real-world drug survival of ixekizumab for psoriasis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Hydrochlorothiazide use and risk of Merkel cell carcinoma and malignant adnexal skin tumors: A nationwide case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence of Immune-mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cohort profile: the clinical 'Psoriasis in Adolescents' (PIA) cohort in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Lithiumpyridinyl-Driven Synthesis of High-Purity Zero-Valent Iron Nanoparticles and Their Use in Follow-Up Reactions

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Necrotic ulcer on the chin of a previously healthy 38-year-old woman

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce.

OBJECTIVES: To investigate the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with psoriasis in Denmark.

METHODS: Using DERMBIO, we examined Danish patients receiving treatment with secukinumab or ixekizumab according to the standard in-label dosing. Kaplan-Meier plots were used to present survival curves.

RESULTS: In all, 368 and 62 patients received treatment with secukinumab and ixekizumab, respectively. In total, 40.7% and 12.9% of secukinumab- and ixekizumab-treated patients were bionaive. Ixekizumab-treated patients had received significantly more previous treatments. Over 12 months, 23.5% and 0.0% of bionaive secukinumab- and ixekizumab-treated patients discontinued therapy, respectively. Drug survival for bionaive and non-naive patients was lower for secukinumab than for ixekizumab. During the maximum 3 years of follow-up, secukinumab drug survival was lowest for patients who had previously been treated with 2 or more biologics, followed by patients treated with secukinumab as their second-ever biologic.

LIMITATIONS: The total number of patients and follow-up time were modest.

CONCLUSIONS: Drug survival was higher for ixekizumab even though secukinumab-treated patients had been treated with significantly fewer biologics before starting this drug.

OriginalsprogEngelsk
TidsskriftJournal of the American Academy of Dermatology
Vol/bind81
Udgave nummer1
Sider (fra-til)173-178
Antal sider6
ISSN0190-9622
DOI
StatusUdgivet - jul. 2019

Bibliografisk note

Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

ID: 57774636